- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213784
Optimized Glycemic Control in Heart Failure Patients With DM2:"Effect on Left Ventricular Function and Skeletal Muscle" (HFDM)
Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:"Effect on Left Ventricular Function and Skeletal Muscle"
The investigators wish to investigate wether a more strict diabetic control improves cardiac function, muscle strength, exercise capacity and decreases symptoms.
The investigators hypothesis is that improving the glycemic control in suboptimized diabetics with heart failure will improve cardiac performance, muscle strength, exercise capacity and decrease symptoms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Region Midtjylland
-
Aarhus, Region Midtjylland, Denmark, 8200
- Dept. of cardiology, Aarhus university hospital Skejby
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ejection fraction =<45%
- Diabetes
- Hba1c =>7,5%
- In anticongestive treatment
- NYHA class 2-4
Exclusion Criteria:
- Severe angina (CCS 3-4)
- Hemodynamic significant heart valve disease
- Congenital heart disease
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: optimized diabetic control
each participant will be assigned to be optimized in a dedicated diabetic clinic
|
We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
|
|
No Intervention: control
participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Left ventricular function
Time Frame: 4 month
|
Left ventricular function will be evaluated using echocardiografi measuring: - 2D Ejection fraction (using an ultrasound agent), global and regional tissue velocity, Strain / strain rate - all measures done during rest and dobutamin stress test. |
4 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
hormonal and metabolic profile
Time Frame: 4 month
|
bloodsamples
|
4 month
|
|
6-minutes hall walk test
Time Frame: 4 month
|
using a hall walk protocol
|
4 month
|
|
Exercise capacity and peak oxygen consumption
Time Frame: 4 month
|
using a treadmill test and continues oxygen consumption measurement
|
4 month
|
|
Muscle strength and mass
Time Frame: 4 month
|
muscle strength: hand grip test
|
4 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Roni R Nielsen, MD, Dept. of cardiology, University hospital Aarhus Skejby
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M20090047
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.